萬泰生物(603392.SH)上市至今股價累計漲幅已達3198.4% 新冠檢測試劑銷量佔公司總體收入比重不大
格隆匯 8 月 3日丨萬泰生物(603392.SH)公佈,公司股票價格,2020年7月30日、7月31日、8月3日連續3個交易日累計漲幅達到27.93%。公司自上市至今,股票價格累計漲幅已達到3198.40%。連續三個交易日累計成交金額為41.62億元,三個交易日累計換手率達到37.37%。公司特別提醒投資者,注意二級市場交易風險。
公司市盈率水平較高,根據同花順iFinD數據顯示,截至2020年8月3日,公司滾動市盈率為523.48,遠高於醫藥製造業的行業滾動市盈率64.91;公司靜態市盈率為599.15,遠高於醫藥製造業的行業靜態市盈率97.60。
公司新冠檢測試劑目前僅有基於發光平台的新型冠狀病毒檢測試劑盒(雙抗原夾心法)取得國內醫療器械註冊證,且新冠檢測試劑銷售量佔公司總體收入比重不大,對公司財務狀況不會產生重大影響。
公司雙價宮頸癌疫苗(HPV2價)上市時間不長,疫苗銷售受市場推廣、消費者接受程度等多方面因素影響,疫苗銷售對於公司利潤的影響存在不確定性。
公司7月30日公告與賽諾菲巴斯德公司簽訂授權協議事項,除首期預付款1000萬美元外,後續的里程碑款以及未來銷售的許可費的收取取決於巴斯德新型輪狀病毒疫苗(主要用於預防A型輪狀病毒引起的兒童腹瀉)研發成功上市。疫苗成功上市可能因受技術、臨牀實驗、政府審批、外部市場環境等多種因素影響,面臨開發週期長、研發風險大、市場風險高的情況,能否實現還存在較大不確定性。
請投資者充分閲讀公告正文表述的相關風險事項。公司特別提醒投資者理性投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.